ABT Reiterated by TD Cowen -- Price Target Maintained at $135

gurufocus.com · 2026-10-16

On October 3, 2023, Abbott Laboratories (ABT) has received a reaffirmation of its 'Buy' rating from TD Cowen, as analyst Joshua Jennings reiterated the price ta

TickrTrends take: TD Cowen's maintained price target of $135 for ABT suggests the analyst sees limited near-term upside from current levels, which aligns with TickrTrends' assessment that the stock is trading below its intrinsic value. For a valuation-focused investor monitoring this Healthcare sector name, the reiteration indicates that consensus expectations remain relatively stable, making any divergence between ABT's actual performance and analyst projections a key metric to watch. The disconnect between a maintained price target and TickrTrends' undervaluation signal may reflect different timeframes or valuation methodologies worth tracking as earnings and market conditions evolve.

Read the full story at gurufocus.com →